Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

746 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial.
Desai AS, Vaduganathan M, Claggett BL, Kulac IJ, Jhund PS, Cunningham J, Borentain M, Lay-Flurrie J, Viswanathan P, Rohwedder K, Amarante F, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Kosiborod M, McMurray JJV, Solomon SD. Desai AS, et al. Among authors: vaduganathan m. J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08452-3. doi: 10.1016/j.jacc.2024.09.004. Online ahead of print. J Am Coll Cardiol. 2024. PMID: 39352340 Free article.
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators. Vaduganathan M, et al. J Cardiovasc Med (Hagerstown). 2012 Jul;13(7):415-22. doi: 10.2459/JCM.0b013e328355a740. J Cardiovasc Med (Hagerstown). 2012. PMID: 22673023 Clinical Trial.
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ, Harinstein ME, Vaduganathan M, Subačius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M; EVEREST Trial Investigators. Greene SJ, et al. Among authors: vaduganathan m. Am J Cardiol. 2012 Dec 1;110(11):1657-62. doi: 10.1016/j.amjcard.2012.07.035. Epub 2012 Aug 21. Am J Cardiol. 2012. PMID: 22917555 Clinical Trial.
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M. Mentz RJ, et al. Among authors: vaduganathan m. Eur J Heart Fail. 2013 Jan;15(1):61-8. doi: 10.1093/eurjhf/hfs139. Epub 2012 Sep 11. Eur J Heart Fail. 2013. PMID: 22968743 Free PMC article. Clinical Trial.
Anticoagulation in heart failure: current status and future direction.
Gheorghiade M, Vaduganathan M, Fonarow GC, Greene SJ, Greenberg BH, Liu PP, Massie BM, Mehra MR, Metra M, Zannad F, Cleland JG, van Veldhuisen DJ, Shah AN, Butler J. Gheorghiade M, et al. Among authors: vaduganathan m. Heart Fail Rev. 2013 Nov;18(6):797-813. doi: 10.1007/s10741-012-9343-x. Heart Fail Rev. 2013. PMID: 22987320 Review.
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M; EVEREST trial investigators. Vaduganathan M, et al. Circ Heart Fail. 2012 Nov;5(6):750-8. doi: 10.1161/CIRCHEARTFAILURE.112.970525. Epub 2012 Oct 9. Circ Heart Fail. 2012. PMID: 23051949 Clinical Trial.
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
Mentz RJ, Chung MJ, Gheorghiade M, Pang PS, Kwasny MJ, Ambrosy AP, Vaduganathan M, O'Connor CM, Swedberg K, Zannad F, Konstam MA, Maggioni AP. Mentz RJ, et al. Among authors: vaduganathan m. Am Heart J. 2012 Dec;164(6):884-92.e2. doi: 10.1016/j.ahj.2012.09.011. Epub 2012 Oct 29. Am Heart J. 2012. PMID: 23194489 Clinical Trial.
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Greene SJ, et al. Among authors: vaduganathan m. Am J Cardiol. 2013 Feb 15;111(4):574-81. doi: 10.1016/j.amjcard.2012.10.042. Epub 2012 Dec 1. Am J Cardiol. 2013. PMID: 23206923 Clinical Trial.
Rehospitalization for heart failure: problems and perspectives.
Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Gheorghiade M, et al. Among authors: vaduganathan m. J Am Coll Cardiol. 2013 Jan 29;61(4):391-403. doi: 10.1016/j.jacc.2012.09.038. Epub 2012 Dec 5. J Am Coll Cardiol. 2013. PMID: 23219302 Free article.
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.
Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, Maggioni A, Mentz RJ, Swedberg K, Zannad F, Gheorghiade M; EVEREST Investigators. Butler J, et al. Among authors: vaduganathan m. J Am Coll Cardiol. 2013 Feb 5;61(5):571-9. doi: 10.1016/j.jacc.2012.10.025. Epub 2012 Dec 12. J Am Coll Cardiol. 2013. PMID: 23246389 Free article. Clinical Trial.
746 results